Baylor College of Medicine

Pediatric hematology-oncology initiative launched in Africa

Tuesday, February 21, 2017

His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama of the Republic of Botswana, the Honorable Minister Dorcas Makgato of the Ministry of Health and Wellness, the Bristol-Myers Squibb Foundation, Texas Children’s Cancer and Hematology Centers (TXCH) and Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children’s Hospital (BIPAI) through public-private partnerships with the governments of Botswana, Uganda and Malawi, announced a $100 million initiative to create an innovative pediatric hematology-oncology treatment network in southern and east Africa. The comprehensive initiative called Global HOPE (Hematology-Oncology Pediatric Excellence) will build long-term capacity to treat and dramatically improve the prognosis of thousands of children with cancer and blood disorders in southern and eastern Africa.

[Read More]

Cell Medica, Baylor partner on cancer treatments

Monday, June 20, 2016

Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, has announced a co-development partnership with Baylor College of Medicine to develop next-generation technologies for engineering immune cells with enhanced functions for the treatment of solid tumors. The collaboration provides Cell Medica with an exclusive license over several Baylor cell and gene technologies and an option to license new products introduced into the co-development partnership by Baylor’s leading research teams in the field of genetically engineered immune cells.

[Read More]

Undiagnosed Diseases Network launches online application portal

Thursday, September 17, 2015

The Undiagnosed Diseases Network (UDN), a clinical research initiative of the National Institutes of Health, has opened an online patient application portal called the UDN Gateway. Introduction of this application system sets the stage for the network to advance its core mission: to diagnose patients who suffer from conditions that even skilled physicians have been unable to diagnose despite extensive clinical investigation. These diseases are difficult for doctors to diagnose because they are rarely seen, have not previously been described or are unrecognized forms of more common diseases.

[Read More]

NIH launches Illuminating the Druggable Genome to find potential drug targets

Wednesday, October 29, 2014

NIH has announced a new collaborative initiative to improve human health by exploring poorly understood genes that have the potential to be modified by medicines. The effort is part of an NIH Common Fund three-year pilot project called Illuminating the Druggable Genome (IDG). For the initial phase of the program, NIH has allocated $5.8 million to eight institutions and for intramural resources.

[Read More]

NIH adds six clinical sites in Undiagnosed Diseases Network

Wednesday, July 2, 2014

The NIH has awarded grants to six medical centers around the country to select from the most difficult-to-solve medical cases and together develop effective approaches to diagnose them. The new clinical sites added to the NIH Undiagnosed Diseases Network (UDN) will conduct clinical evaluation and scientific investigation in cases that involve patients with prolonged, undiagnosed conditions.

[Read More]